Bright Minds Biosciences Inc. DRUG
Annual
Quarterly
No annual revenue total was found in BRIGHT MINDS BIOSCIENCES INC.'s SEC filings.
Bright Minds Biosciences Inc. (DRUG) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
4.52M
+1.3% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRUG (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1827401
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 2, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Oct 1, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jun 3, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jan 20, 2026 |
All 180 Bright Minds Biosciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.